Company intelligence / Profile preview
Akeso Biopharma
Guangzhou, Guangdong, Chinachictr.org.cn ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Akeso/Kangfang has developed over fifty innovative drug candidates with three drugs already launched commercially. Its portfolio includes first-in-class/best-in-class bispecific antibodies and multiple pivotal Phase III trials. Yiwosi® achieved a record licensing deal for a Chinese innovative drug. The company’s ACE Platform enables end-to-end biologic discovery through commercialization. It focuses on oncology, autoimmunity, and metabolic disease with global expansion underway.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodies (Tetrabody technology)Antibody-drug conjugates (ADC)mRNA therapeuticsCell therapy
- Industry
- Biotech
02
Drug pipeline
22 assets21 more assets in the full pipeline.
Request access →03
Partnerships
Summit Therapeutics – exclusive rights for Yiwosi® in US/EU/Japan ($5B deal)China Biopharmaceuticals – co-development/commercialization of penpulimabGE Healthcare – manufacturing collaboration using FlexFactory™ tech
Beyond the preview
Go deeper on Akeso Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akeso Biopharma.